Stockreport

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data [Yahoo! Finance]

Cassava Sciences, Inc.  (SAVA) 
Last cassava sciences, inc. earnings: 8/12 08:30 am Check Earnings Report
PDF Simufilam continued to demonstrate an overall favorable safety profile Cassava's Alzheimer's disease development program with simufilam will be completely discontinue [Read more]